Literature DB >> 34153313

Kappa opioid receptor modulation of endometriosis pain in mice.

Alejandra Escudero-Lara1, David Cabañero2, Rafael Maldonado3.   

Abstract

The kappa opioid receptor is a constituent of the endogenous opioid analgesia system widely expressed in somatosensory nervous pathways and also in endometrial tissues. This work investigates the possible involvement of kappa opioid receptor on the nociceptive, behavioral and histopathological manifestations of endometriosis in a murine model. Female mice receiving endometrial implants develop a persistent mechanical hypersensitivity in the pelvic area that is stronger during the estrus phase of the estrous cycle. The kappa opioid receptor agonist U50,488H produces a dose-dependent relief of this mechanical hypersensitivity, regardless of the cycle phase. Repeated exposure to a low dose of U50,488H (1 mg/kg/day s.c. for one month) provides sustained relief of mechanical hypersensitivity, without tolerance development or sedative side effects. Interestingly, this treatment also inhibits a decreased rearing behavior associated with spontaneous pain or discomfort in endometriosis mice. This KOR-mediated pain relief does not prevent the anxiety-like behavior or the cognitive impairment exhibited by endometriosis mice, and the growth of endometriotic cysts is also unaltered. These data provide evidence of strong pain-relieving properties of kappa opioid receptor stimulation in female mice with endometriosis pain. The persistence of affective and cognitive manifestations suggests that these comorbidities are independent of pelvic pain and simultaneous treatment of these comorbidities may be necessary for successful management of endometriosis.
Copyright © 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Chronic pelvic pain; Endometriosis; Female; Kappa opioid receptor; U50,488H

Mesh:

Substances:

Year:  2021        PMID: 34153313     DOI: 10.1016/j.neuropharm.2021.108677

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  2 in total

Review 1.  The Kappa Opioid Receptor: A Promising Therapeutic Target for Multiple Pathologies.

Authors:  Martin L Dalefield; Brittany Scouller; Rabia Bibi; Bronwyn M Kivell
Journal:  Front Pharmacol       Date:  2022-06-20       Impact factor: 5.988

2.  Effects of dezocine on morphine tolerance and opioid receptor expression in a rat model of bone cancer pain.

Authors:  Lin-Xin Wu; Yan-Peng Dong; Qian-Mei Zhu; Bo Zhang; Bo-Lun Ai; Tao Yan; Guo-Hua Zhang; Li Sun
Journal:  BMC Cancer       Date:  2021-10-20       Impact factor: 4.430

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.